secwatch.observer — SEC 8-K summary
======================================

Issuer:     Artiva Biotherapeutics, Inc. (ARTV)
CIK:        0001817241
Form:       8-K
Filed at:   2024-10-22T23:59:59+00:00
Accession:  0001193125-24-241059
Event type: leadership
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Artiva appoints Alison Moore Ph.D. as Class III director and committee member
-----------------------------------------------------------------------------

- Alison Moore appointed as Class III director with term expiring at 2027 annual meeting; also joins Technical Operations Committee.
- Dr. Moore is Chief Technical Officer at Codexis (since Oct 2024); previously CTO/EVP at Allogene Therapeutics and SVP at Amgen.
- Receives annual cash retainer of $40,000 for board service and $15,000 for Technical Operations Committee service.
- Granted option to purchase 27,500 shares, one-third vested immediately, remainder vesting monthly over two years.
- Will receive automatic annual option grants of 13,750 shares at each annual meeting, vesting over one year.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1817241/000119312524241059/0001193125-24-241059-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1817241/000119312524241059/d855080d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-241059

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer